Skip to contentB
BioCorRx Inc.
B
BICXBioCorRx Inc. Q2 2026 · 10-Q
Revenue$87.97K$87.97K−50.6% vs Q2 2025 Net Income-$964.77K-$964.77KN/M vs Q2 2025 EPS Diluted-$0.03-$0.03N/M vs Q2 2025 Operating Income-$1,465,538N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioCorRx Inc. · CIK 1443863 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-1666.0%−872.7 pt vs Q2 2025
Net margin-1096.7%−404.7 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 14, 2026 · 45 d after period end